How Mylan is meeting challenges in sustainability
Mylan works with industry associations and key stakeholders to improve sustainability of the healthcare system. Jacek Glinka, President, Mylan Europe, explains how...
List view / Grid view
Mylan works with industry associations and key stakeholders to improve sustainability of the healthcare system. Jacek Glinka, President, Mylan Europe, explains how...
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit at Boehringer Ingelheim, tells EPR about some of his company’s achievements that he is most proud of, and describes how it will face the digital challenge...
Marc Princen, Executive Vice President and President Allergan International, explains how Allergan’s novel ethos and innovative approach makes it stand out from the crowd...
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
The emergence of big data, technological innovations and advancements in scientific research is set to be transformative for the pharmaceutical industry, providing faster access to insights that can drive more informed decision making and accelerate drug development. Dr Chris Barber, CEO of Lhasa Limited, looks at what is next for…
Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe, discusses some of the company’s achievements...
Microbiological contamination of non-sterile medicinal products is an infrequent, but longstanding and recurring issue. But there is no ‘one size fits all’ approach towards objectionable organisms, says David Elder...
Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further...
When thinking about the future of the pharmaceutical sector, it can be difficult to pinpoint a specific focus as there are a wide range of challenges that come into consideration across all stages of development and manufacturing. Dr Lynne Murdoch, Business Manager – Microbiology, Wickham Laboratories, considers some key points....
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
For Pfizer, putting patients first guides its actions, informs its strategic decisions and unifies colleagues in every region and function across the company. Beatriz Faro, Regional President, Internal Medicine, International Developed Markets at Pfizer, explains how the company’s philosophy is taking the business forward...
Since 2007, the EMA has approved 31 biosimilar products1 and refused or withdrawn around five. The FDA, however, since the enactment of the Biologics Price Competition and Innovation Act (BPCIA) in 2009,2 has licensed six products under PHS 351(k) of the Public Health Service (PHS) Act; approved one product under…
Particle size reduction is a fast and cost-effective answer to increasing the exposure of poorly soluble oral drugs by increasing surface area and thereby improving dissolution rate. This approach will only work for DCS IIa1 drugs where dissolution rate is the rate-limiting factor for absorption. This may be applicable to…
Among the list of over 300 FDA and EMA approved biopharmaceutical products, around 50% are freeze-dried – indicating that freeze-drying is the preferred way of stabilising biopharmaceutical drug products that are unstable in aqueous solution, despite the high cost and long processing time linked to this manufacturing technique.1,2
At least some degree of solubility in water is necessary for active ingredients in pharmaceutical products to be effective in vivo. However, as efforts to discover and synthesise new active ingredients are pursued by industrial and academic medicinal chemists, achieving sufficient aqueous solubility can often be a significant limitation to…